Fingerprint
Dive into the research topics of 'Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, M. Catherine Pietanza, Bilal Piperdi, Thomas Burke
Research output: Contribution to journal › Article › peer-review
27
Scopus
citations